# US 2025/0154236 A1 · Prevention and treatment of headaches

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154236 A1
- Document ID: US20250154236A1
- Status: Published application
- Kind: A1
- Application number: 18/832,579
- Filed: 2023-01-30
- Published: 2025-05-15
- Earliest claimed: 2022-01-31
- Assignees: GlaxoSmithKline Intellectual Property (No. 3) Limited; 23andMe, Inc.
- Applicants: GlaxoSmithKline Intellectual Property (No. 3) Limited; 23andMe, Inc.
- Inventors: Gareth Trevor YOUNG; Caixia JIA; Wenjie REN; Dominic Samuel BERNS; Adam Mohamed NAGUIB
- Web page: https://patentgrep.com/patent/US20250154236A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 25/06: Antimigraine agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to use of artemin inhibitors in prevention or treatment of headaches such as migraine.

## Claims

### Claim 1

A method of preventing or treating migraine a subject in need thereof, comprising administering to the subject an inhibitor of human artemin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human artemin comprises the sequence set out in SEQ ID NO: 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human artemin comprises the sequence set out in SEQ ID NO: 2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject is a human subject detected to having an Artemin comprising the sequence set out in SEQ ID NO: 1.

### Claim 6 (depends on 1)

The method of claim 1, wherein the use comprises administering is a subcutaneous administration.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitor is present in an aqueous solution.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inhibitor is a humanized monoclonal antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the inhibitor is a bispecific antibody targeting CGRP and the human artemin.

### Claim 10 (depends on 1)

The method of claim 1, wherein the inhibitor is a bispecific antibody targeting Substance P and the human artemin.

### Claim 11 (depends on 1)

The method of claim 1, wherein the use method is the prevention of migraine.

### Claim 12 (depends on 11)

The method of claim 11, wherein a reduction in mean monthly migraine-occurrence days is at least 10% greater for a population of patients administered with the inhibitor compared to a placebo or a therapeutic agent directly targeting CGRP.

### Claim 13 (depends on 11)

The method of claim 11, wherein the 50% responder rate is higher for a population of patients administered with the inhibitor compared to a placebo or a therapeutic agent directly targeting CGRP.

### Claim 14 (depends on 1)

The method of claim 1, wherein the use method is the treatment of migraine.

### Claim 15 (depends on 14)

The method of claim 14, wherein a percentage of patients that are pain free 2 hours after administration of the inhibitor is at least 10% higher for a population of patients administered with the inhibitor compared to a population of patients administered with a placebo or a therapeutic agent directly targeting CGRP.

### Claim 16 (depends on 14)

The method of claim 14, wherein a percentage of patients that are pain free 2 hours after administration of the inhibitor and do not use rescue medication or relapse within 24 hours after administration of the inhibitor is at least 10% higher compared to a population of patients administered with a placebo or a therapeutic agent directly targeting CGRP.

### Claim 17 (depends on 12)

The method of claim 12, wherein the therapeutic agent directly targeting CGRP is erenumab, fremanezumab, galcanezumab, eptinezumab, ubrogepant, rimpegepant, or atogepant.

### Claim 18 (depends on 13)

The method of claim 13, wherein the therapeutic agent directly targeting CGRP is erenumab, fremanezumab, galcanezumab, eptinezumab, ubrogepant, rimpegepant, or atogepant.

### Claim 19 (depends on 15)

The method of claim 15, wherein the therapeutic agent directly targeting CGRP is erenumab, fremanezumab, galcanezumab, eptinezumab, ubrogepant, rimpegepant, or atogepant.

### Claim 20 (depends on 16)

The method of claim 16, wherein the therapeutic agent directly targeting CGRP is erenumab, fremanezumab, galcanezumab, eptinezumab, ubrogepant, rimpegepant, or atogepant.
